NCT01696604View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

September 26, 2012

Primary Completion Date

May 3, 2013

Study Completion Date

May 3, 2013

Conditions

Cachexia

Interventions

DRUG

GSK2849466

GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.

DRUG

Placebo

Matching placebo capsules will be available.

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01696604 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter